目的：探讨经皮冠状动脉介入（PCI）术后影响氯吡格雷血小板抑制率的相关因素，并建立预测模型。方法：收集PCI术后予阿司匹林100 mg·d^-1及氯吡格雷75 mg·d^-1抗血小板治疗461例患者，连续服用5 d后晨起空腹抽取静脉血5 ml进行血栓弹力图检测。应用单因素分析探索二分类变量及等级资料对二磷酸腺苷诱导的血小板抑制率（ADP%）的影响，利用Spearman分析探索ADP%与连续性变量的相关性，并基于多重线性回归模型预测PCI术后患者ADP%。结果：单因素分析显示糖尿病（P=0.005）、CYP2C19*2携带（P=0.012）为ADP%的独立预测因素，相关性分析显示血红蛋白（P=0.001）、白细胞计数（WBC）（P=0.041）、肾小球滤过率（eGFR）（P=0.033）及支架长度（P=0.041）与ADP%呈显著相关。基于多重线性回归模型构建PCI术后患者ADP%的预测公式为：ADP%=34.569+0.246×血红蛋白-6.357×糖尿病-5.623×CYP2C19*2携带+0.665×eGFR+0.954×WBC-0.099×支架长度（r²=9.6%，P=0.001）。结论：糖尿病、CYP2C19*2携带、eGFR、WBC及血红蛋白为PCI术后影响氯吡格雷血小板抑制率的独立预测因素，ADP%的预测公式可解释9.6%的氯吡格雷血小板抑制率的变异度。

[1] 齐乐,陈洪.不同质子泵抑制剂与抗血小板药物联用时心血管安全性Meta分析[J].东南大学学报(医学版),2013,32(3):308-316.
[2] 赵青,张抒扬.氯吡格雷抵抗的早期诊断及临床对策[J].中华临床医师杂志,2012,6(2):423-425.
[3] BUONAMICI P,MARCUCCI R,MIGLIORINI A,et al.Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis[J].J Am Coll Cardiol,2007,49(24):2312-2317.
[4] 张会超,聂恒,芮浩淼,等.抗纤益心方通过TGF-β/Smads信号通路改善糖尿病心肌病大鼠心肌纤维化和心功能的研究[J].东南大学学报(医学版),2018,37(3):415-419.
[5] ANGIOLILLO D J,BERNARDO E,RAMFREZ C,et al.Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment[J].J Am Coll Cardiol,2006,48(2):298-304.
[6] PARK S H,KIM W,PARK C S,et al.A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure[J].Am J Cardiol,2009,104:1292-1295.
[7] MULLER C,CAILLARD S,JESEL L,et al.Association of estimated GFR with platelet inhibition in patients treated with clopidogrel[J].Am J Kidney Dis,2012,59:777-785.
[8] JAIN N,LI X,ADAMS-HUET B,et al.Differences in whole blood platelet aggregation at baseline and in response to aspirin and aspirin plus clopidogrel in patients with versus without chronic kidney disease[J].Am J Cardiol,2016,117:656-663.
[9] FERREIRO J L,GOMEZ-HOSPITAL J A,ANGIOLILLO D J.Platelet abnormalities in diabetes mellitus[J].Diab Vasc Dis Res,2010,7(4):251-259.
[10] JAKL M,SEVCIK R,CERAL J,et al.Mean platelet volume and platelet count:overlooked markers of high on-treatment platelet reactivity and worse outcome in patients with acute coronary syndrome[J].Anadolu Kardiyol Derg,2014,14:85-86.
[11] TRESUKOSOL D,SUKTITIPAT B,HUNNANGKUL S,et al.Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease[J].PLoS One,2014,9(10):e110188.
[12] HULOT J S,COLLET J P,SILVAIN J,et a1.Cardiovascular risk in clopidogrel treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration:a systematic meta-analysis[J].J Am Coil Cardiol,2010,56(2):134-143.
[13] LIU T,YIN T,LI Y,et al.CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention[J].Coron Artery Dis,2014,25(5):412-420.
[14] SHULDINER A R,O'CONNELL J R,Bliden K P,et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA,2009,302(8):849-857.
[15] HOCHHOLZER W,TRENK D,FROMM M F,et al.Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement[J].J Am Coll Cardiol,2010,55(22):2427-2434.